Progentec Diagnostics, Inc.

11:30 AM - 11:45 AM (EDT), Wednesday, June 7, 2023 ・ Session Room 104A
Progentec is committed to improving access and health outcomes for patients in therapeutic areas with a high level of unmet need by combining clinically validated diagnostic interventions with state-of-the-art digital and virtual technologies. Through collaborations with research institutions and health practitioners worldwide, Progentec is working to reduce mortality and morbidity while improving care management and service delivery for chronic health conditions.
Company Type:
Privately Funded Company
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
aiSLE Dx Laboratory Tests: 1. aiSLE DX Flare Risk Index to predict lupus flares in the next 12 weeks, 2. aiSLE DX Disease Activity Index - to measure current disease levels in lupus patients
Development Phase of Primary Product:
Multiple Products in Market
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Chairman & CEO
Progentec Diagnostics, Inc.